Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients

BACKGROUND: Bevacizumab, an anti-VEGF monoclonal antibody, has recently emerged as a new option for severe forms of hereditary hemorrhagic telangiectasia (HHT). Its utilization in this orphan disease has rapidly spread despite the lack of randomized trials and international guidelines. The objective...

Descripción completa

Detalles Bibliográficos
Autores principales: Guilhem, Alexandre, Fargeton, Anne-Emmanuelle, Simon, Anne-Claire, Duffau, Pierre, Harle, Jean-Robert, Lavigne, Christian, Carette, Marie-France, Bletry, Olivier, Kaminsky, Pierre, Leguy, Vanessa, Lerolle, Nathalie, Roux, Dominique, Lambert, Marc, Chinet, Thierry, Bonnet, Delphine, Dupuis-Girod, Sophie, Rivière, Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708634/
https://www.ncbi.nlm.nih.gov/pubmed/29190827
http://dx.doi.org/10.1371/journal.pone.0188943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708634/
https://www.ncbi.nlm.nih.gov/pubmed/29190827
http://dx.doi.org/10.1371/journal.pone.0188943

Ejemplares similares